abstract |
A pharmaceutical formulation which comprises a parenterally acceptable carrier or a diluent and estramustine phosphate in admixture with human albumin, wherein the weight ratio of estramustine phosphate to human albumin is from about 1:5 to about 1:0.3. The formulation can be administered according to a combined chemotherapy regimen in association with one or more chemotherapeutic agents. The formulation also enables estramustine phosphate to be administered with no side effects at the side of injection. |